We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Articles

Results 1 to 3 of 3
Most popular |Most recent


U.S. - What does the Impression Products v. Lexmark decision mean for drug companies? 5 takeaways

USA - September 11 2017 Last May, the U.S. Supreme Court issued a highly-anticipated decision in Impression Products, Inc. v. Lexmark Int’l, Inc., reversing the Federal...

U.S. - Protecting IP in Digital Health deals

USA - November 18 2016 Industry sources estimate that more than $4 billion worth of deals in digital health have been signed globally this year so far, as pharmaceutical...

New FDA draft guidance on contract manufacturing quality agreements

USA - June 3 2013 On 28 May 2013, FDA issued a draft guidance for the industry, titled Contract Manufacturing Arrangements for Drugs: Quality Agreements. The release...

Robert Church, James R. Johnson.